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2ABSTRACT
Ciliary neurotrophic factor and bone morphogenetic proteins induce astrocytogenesis in
the developing rat brain by stimulating STAT- and Smad-dependent signaling,
respectively. We previously found that stimulation of the cAMP-dependent signaling
pathway also triggers differentiation of cerebral cortical precursor cells into astrocytes,
providing an additional mechanism to promote astrocyte differentiation. In this study,
we show that pituitary adenylate cyclase-activating polypeptide (PACAP), but not the
related vasoactive intestinal peptide, induces astrocyte differentiation of cortical
precursor cells, even after a transient exposure. Cortical precursors were found to
express predominantly the short isoform of the PACAP-specific PAC1 receptor, which
couples to adenylate cyclase. Consistent with this notion, we determined that exposure
of cortical precursors to PACAP resulted in a dose-dependent increase in cAMP
production. Pretreatment of cells with the cAMP antagonist Rp-cAMPS prevented
astrocyte differentiation. Thus, PACAP acts as an extracellular signal to trigger cortical
precursor cell differentiation into astrocytes via stimulation of intracellular cAMP
production.
3INTRODUCTION
During development, the central nervous system becomes populated by cells
that arise from neuroepithelial precursors that proliferate in the ventricular zone of the
neural tube. Those cells, generated through several rounds of cell division, differentiate
to yield different types of neurons and glial cells, following a tightly regulated spatial
and temporal arrangement. It has become widely accepted that neural progenitor cells
that proliferate in the embryonic central nervous system are pluripotential. By virtue of
this property, they have the capacity to generate different neuronal or glial phenotypes
in response to specific extracellular signals that instruct them to follow specific
pathways of differentiation. Thus, phenotypic diversity of cells in the central nervous
system appears to be due to a large extent to the nature of the neurotrophic factors that
act on precursor cells at a particular time during development.
In the developing rat brain, production of neurons takes place during a period of
time spanning from embryonic day 13 (E13) to E19, approximately, whereas generation
of astrocytes takes place towards the end of the gestational period and proceeds
postnatally (Jacobson, 1993). Several neurotrophic factors have been discovered that
limit the differentiation capacity of progenitor cells and trigger their phenotypic
transition toward neuronal or glial lineages. These neurotrophic factors regulate
neurogenesis, gliogenesis and proliferation of neural cells, and  include, among others,
basic fibroblast growth factor (bFGF), ciliary neurotrophic factor (CNTF), bone
morphogenetic proteins (BMPs), platelet-derived growth factor (PDGF), neurotrophin
3, brain-derived neurotrophic factor (BDNF) and neuregulins (Bonni et al., 1997; Gross
et al., 1996; Johe et al., 1996; Park et al., 1999; Buonanno and Fischbach, 2001).
4Among neurotrophic factors discovered so far, at least two, CNTF (Bonni et al.,
1997; Johe et al., 1996; Park et al., 1999; Shimazaki et al., 2001) and BMP-2 (Gross et
al., 1996; Mabie et al., 1999; Nakashima et al., 2001) appear to be major signaling
factors that act on neural precursors to induce astrocyte differentiation during brain
development. Integrity of receptors for CNTF is required to ensure adequate
intracellular signaling to generate proper number of astrocytes, as indicated by targeted
gene disruption via homologous recombination in mice (Koblar et al., 1998; Nakashima
et al., 1999; Ware et al., 1995). Intracellular signaling by CNTF relies on the activation
by phosphorylation of the receptor-associated JAK and STAT proteins, which results in
the stimulation of GFAP gene expression mediated by the transcriptional
transactivation properties of STAT1 and STAT3 (Bonni et al., 1997; Nakashima et al.,
1999; Park et al., 1999; Rajan and McKay, 1998; Sun et al., 2001). Absence of
astrocyte differentiation in cells that lack receptors for CNTF can be overcome by
treatment with BMP-2 (Koblar et al., 1998), indicating that neural precursors are able to
respond to different astrocyte differentiation stimuli through the activation of
independent intracellular signaling pathways. The signaling pathway activated by
members of BMP family involves activation of Smad transcription factors (Ebendal et
al., 1998; Zhang et al., 1998), that can act on the GFAP promoter independently or in
synergy with CNTF-activated STAT proteins to induce astrocyte differentiation
(Nakashima et al., 1999; Sun et al., 2001).
Previous studies carried out in our laboratory led to the identification of an
additional or alternative mechanism for the generation of cortical astrocytes from
undifferentiated precursor cells based on the activation of the cAMP-dependent signal
transduction pathway (McManus et al., 1999). We found that treatment of cortical
precursors maintained in vitro with the cAMP analog 8Br-cAMP or with forskolin
5results in a potent antimitotic effect and an increase in GFAP gene expression, along
with changes in the cellular morphology that accompany the differentiation response.
Those studies suggested the possible existence of extracellular factors in the developing
cortex that promote astrocytogenesis by acting on G protein-coupled receptors that
activate cAMP-dependent signaling. In the present study, we report that treatment of
cortical precursor cells with pituitary adenylate cyclase activating polypeptide
(PACAP), a member of the vasoactive intestinal peptide (VIP)/secretin/glucagon
family, results in elevated levels of cAMP and astrocyte differentiation.
RESULTS
Exposure of cortical precursor cells to brain monoamines does not induce
astrocyte differentiation
Based on our previous observation that cAMP stimulation induces astrocyte
differentiation of cortical precursor cells, we sought to identify extracellular factors,
such as monoamines and peptides, that could exert this action during development by
acting on G protein-coupled receptors in the embryonic central nervous system. The
monoamines serotonin, noradrenaline and dopamine are present in axons that originate
in the brainstem and midbrain, reaching the developing cerebral cortex before the onset
of gliogenesis. Receptors for these monoamines are expressed in neural precursors in
the developing brain, and there is evidence indicating that they have effects on cortical
development (Lauder, 1993; Lavdas et al., 1997; Levitt et al., 1997; Naqui et al., 1999).
For this reason, we tested whether primary precursor cells from embryonic rat cortex
differentiate into astrocytes after exposure to these substances.
Primary cortical cells prepared from E17 rat brains cultured in defined medium
in the presence of bFGF (20 ng/ml) are proliferating, nestin-positive neuroepithelial
6precursors (McManus et al., 1999). We treated these cells with serotonin, noradrenaline
or dopamine for two days after withdrawal of bFGF. As positive controls, we used cells
treated in parallel with 8Br-cAMP (McManus et al., 1999). Processing of these cells for
immunocytochemistry for GFAP revealed that astrocyte differentiation, evidenced by
morphological changes and GFAP immunoreactivity, was detected only in cells treated
with 8Br-cAMP, but not in cells treated with any of the monoamines (Fig. 1A). This
lack of effect of monoamines was not likely to be due to absence of appropriate
membrane receptors on cultured cortical precursors, because we observed
phosphorylation of transcription factor CREB within minutes of treatment with 8Br-
cAMP or monoamines, as evidenced by western immunoblot with a specific anti-
phospho-CREB antiserum (Fig. 1B).
PACAP induces astrocyte differentiation of cortical precursor cells
We then turned our attention to neuropeptides, as a role for some of them in
neural development has been suggested (Cameron et al., 1998). Among them, we
considered PACAP and the closely related VIP (vasoactive intestinal peptide), because
PACAP is known to increase intracellular levels of cAMP by activating adenylate
cyclase (D'Agata et al., 1996; Grimaldi and Cavalaro, 1999; Lu and DiCicco-Bloom,
1997; Spengler et al., 1993; Vaudry et al., 1998).
As in previous experiments, primary cortical cells from E17 rat brains were
cultured in defined medium in the presence of bFGF for at least 24 hours after plating,
and bFGF was withdrawn prior to treatment with PACAP. Exposure of cells to PACAP
resulted in a concentration-dependent increase in the number of GFAP-positive cells
generated over a period of two days in culture (Fig. 2A). In contrast with the results
obtained with PACAP, cells treated in parallel with the structurally related VIP did not
7exhibit morphological changes and did not become immunoreactive for GFAP (Fig.
2A). The observed GFAP immunoreactivity was correlated with an increase in GFAP
expression by Western immunoblot (Fig. 2B).
Immunocytochemical analyses confirmed that withdrawal of bFGF did not
significantly alter nestin immunostaining, and that the number of cells that appeared
positive for GFAP was less than 7% after two days, consistent with our own previous
studies (McManus et al., 1999). In contrast, in dishes in which bFGF had been replaced
with PACAP (100 nM), most cells had become GFAP-positive after 2 days, and had
undergone significant morphological changes, acquiring a stellate morphology typical
of astrocytes and extending cellular processes (Fig. 3). These processes developed with
time, becoming morphologically more elaborate and reaching lengths of up to 50-100
µm after 5 days. In addition, treatment of cortical precursor cells with PACAP led to
downregulation of the neuroepithelial precursor marker nestin (Fig. 3). Finally,
PACAP-treated cells also expressed S100β but did not become immunoreactive for
MAP-2, NCAM, calbindin, or galactocerebroside (not shown), suggesting that PACAP
acts on cortical precursor cells to promote astrocyte differentiation without influencing
neuronal or oligodendroglial lineages.
It has been reported that short exposure of neural precursor cells to specific
neurotrophic signals is sufficient to induce their differentiation towards neuronal of
glial phenotypes, a response that persists even after the inducing agent has been
withdrawn (Park et al., 1999; Williams et al., 1997). To determine whether transient
exposure to PACAP can induce astrocyte differentiation, cortical precursors were
treated with PACAP for different periods of time after bFGF withdrawal. Processing of
cells for GFAP immunocytochemistry revealed that PACAP can initiate astrocyte
8differentiation even after a pulse of treatment lasting only 30 minutes, as assessed two
days after the onset of treatment (Fig. 4).
PACAP decreases proliferation of cortical precursors
To determine whether primary cortical cells prepared from E17 rat brains
decrease their proliferation rate in response to PACAP, as has been described for neural
precursors derived from embryos obtained at an earlier developmental stage, we
determined the relative number of cells that incorporate bromodeoxyuridine (BrdU) in
the presence or absence of PACAP. In these experiments, cells were treated with
PACAP (100 nM) for 16 hours in the presence of bFGF, and BrdU (10 µM) was added
during the last 5 hours. When cells were maintained in the presence of bFGF alone, the
percentage of them that incorporated BrdU was 67 + 6.2 (mean + s.e.m.). In contrast, in
the presence of PACAP, the percentage of cells labeled with BrdU was reduced to 36 +
2.9. This effect was specific, because a similar treatment with VIP (100 nM) resulted in
a proportion of BrdU-labeled cells not significantly different from controls (60 + 5.1%).
These results are consistent with previous findings showing that PACAP provides a
potent antimitotic signal for cortical precursor cells (Lu and DiCicco-Bloom, 1997;
Nicot and DiCicco-Bloom, 2001; Suh et al., 2001; Carey et al., 2002), and with our
previous observations of the antiproliferative effects of cAMP stimulation on neural
precursors (McManus et al., 1999).
Cortical precursor cells express PACAP type I receptors
The capacity of PACAP to induce astrocyte differentiation suggests the presence
of specific receptors whose activation is responsible for this effect. Thus, we initiated
experiments to characterize PACAP receptor isoforms expressed by these cells.
9PACAP can bind specifically to G protein-coupled receptors encoded by at least
three different genes. These receptors are known as PAC1, which is selective for
PACAP, and VPAC1 and VPAC2, both of which exhibit similar affinities for VIP and
PACAP (reviewed in Harmar et al., 1998). To determine whether one or more of these
receptors are expressed in primary cortical precursor cells, we carried out RT-
PCR/Southern blot hybridization experiments for the amplification of specific
transcripts corresponding to each type of receptor. These experiments indicated that
cortical precursor cells express predominantly the PACAP-selective PAC1 receptor
(Fig. 5). Significantly lower levels of VPAC2 receptor transcripts were observed,
whereas transcripts encoding the VPAC1 receptor were undetectable (Fig. 5).
In G protein-coupled receptors with seven transmembrane-spanning domains,
the third intracellular loop regulates coupling to G proteins that link to second
messenger pathways (Strader et al., 1995). The PAC1 receptor exhibits different
isoforms depending on the presence or absence of one or two 28 amino acid domains,
named Hip and Hop, inserted into the third intracellular loop (Spengler et al., 1993)
(Fig. 6A). The Hip and Hop domains, are encoded by two different exons, and affect
the signal transduction pathways activated upon peptide binding to the PAC1 receptor
(Spengler et al., 1993). To determine which one of the PAC1 receptor isoforms are
expressed in primary cortical precursor cells, we carried out RT-PCR/Southern blot
hybridization experiments, using specific oligonucleotides as PCR primers or internal
probes, as indicated in Fig. 6A.
These experiments revealed that the most abundant transcripts in these cells
correspond to the short isoform that lacks Hip and Hop domains (Fig. 6B), although
transcripts with one of these two domains, mostly the Hop domain, were also detected
(Fig. 6B). Notably, we observed that treatment of cortical precursors with 1 mM 8Br-
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cAMP, which induces astrocyte differentiation of these cells as described above, results
in a disappearance of the band corresponding to the Hip or Hop isoforms, and in an
apparent increase in the intensity of the band corresponding to the short receptor
isoform (Fig. 6C). These results indicate that differentiation of astrocytes is
accompanied by changes in the relative proportion of PAC1 receptor isoforms such that
the expression of the short isoform, which couples to cAMP production, is favored over
the expression of the Hip or Hop isoforms, which also activate the
polyphosphoinositide-specific phospholipase C-dependent signaling pathway (Nicot
and DiCicco-Bloom, 2001; Spengler et al., 1993). This circumstance could be
important during neural development, as the short PAC1 receptor isoform has been
associated to inhibition of proliferation of neural cells, and the PAC1Hop isoform with
proliferative effects (Nicot and DiCicco-Bloom, 2001).
Exposure of cortical precursor cells to PACAP results in elevated levels of
intracellular cAMP
As mentioned earlier, PACAP receptors use the cAMP-dependent pathway as a
major intracellular signaling mechanism of peptide activation. Therefore, we
determined intracellular levels of cAMP in primary cultures of cortical precursor cells
following treatment with PACAP. For these experiments cells were treated with
PACAP or VIP in the presence of 2 mM isobutylmethylxantine (IBMX). Control cells
were treated with IBMX only. Cells were harvested 15 minutes after the onset of
treatment, and cAMP levels were determined by radioimmunoassay, using a cAMP-
specific antiserum provided by Dr. E. Schipani (Massachusetts General Hospital,
Boston).
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Levels of intracellular cAMP were undetectable in control cells but increased
significantly after exposure of cells to PACAP (Fig. 7A). Treatment of cells with VIP
also resulted in increased levels of cAMP in these cells, but this response was
significantly smaller than the one observed with PACAP (Fig. 7A).
To further support the notion that the differentiating response of cortical
precursors to PACAP is due to the observed increase in intracellular levels of cAMP,
we investigated whether blockade of intracellular cAMP effectors with the cAMP-
specific antagonist Rp-cAMPS would prevent the differentiation of astrocytes by
PACAP. We observed that cells pretreated with Rp-cAMPS (100 µM) added 5 minutes
before PACAP (100 nM), did not differentiate into astrocytes, as did those treated only
with PACAP (Fig. 7B).
DISCUSSION
Our study shows that PACAP can induce astrocyte differentiation of cortical
precursor cells. This effect is due to the stimulation of intracellular cAMP levels
following activation of PAC1 receptors, a notion supported by the expression of this
type of receptors on the target cells, by the observed elevation of intracellular levels of
cAMP within minutes of the onset of PACAP treatment, and by inhibition of PACAP-
induced astrocytogenesis by the cAMP antagonist Rp-cAMPS. Together with our
previous studies indicating that cAMP-stimulation induces astrocyte differentiation of
cortical precursor cells instructively (McManus et al. , 1999), our data provide evidence
in support of the notion that the PACAP-cAMP pathway provides an alternative
signaling route to astrocyte differentiation in addition to those provided by the
previously described CNTF-STAT and BMP-Smad signaling pathways.
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The notion that PACAP can influence cortical astrocyte differentiation is also
consistent with the observed expression of both PACAP and PACAP receptors in the
developing cortex. Thus, studies carried out by Skoglosa et al. (1999), Jaworski and
Proctor (2000); and Suh et al. (2001) using both in situ hybridization and
immunohistochemistry show that in the developing cortex both PACAP and the PAC1
receptor are expressed at significantly high levels in the ventricular zone during late
gestation and postnatally. Since the ventricular zone contains proliferating precursor
cells that differentiate during cortical development, and astroglial cells are generated
there at a time coincident with PACAP and PAC1 receptor expression, it is likely that
in vivo PACAP influences cortical gliogenesis.
Differentiation to acquire specific cellular phenotypes in the developing brain
coincides with the withdrawal of neuroepithelial precursors from the cell cycle.
Therefore, it is possible that the same factors that instruct cells towards differentiation
act also as signals to inhibit mitosis. This would occur during development even in the
presence of endogenous mitogens, such as bFGF, that ensure the generation of
appropriate numbers of cells. Although PACAP can stimulate proliferation of specific
types of neural cells (Lee et al., 2001; Lu et al., 1998), it is well documented, and our
data confirm, that this peptide has a potent antimitotic effect on cortical precursor cells
of the developing central nervous system (Carey et al., 2002; Lu and DiCicco-Bloom,
1997; Lu et al., 1998; Nicot and DiCicco-Bloom, 2001; Suh et al., 2001).
Previous studies indicate that PACAP can exert different developmental actions
in the central nervous system (Lee et al., 2001; Lu and DiCicco-Bloom, 1997; Zupan et
al., 1998). Recently, in experiments involving transuterine intraventricular
administration of PACAP into developing rat brains, Suh et al. (Suh et al., 2001)
suggested that PACAP affects neuronal lineages without altering gliogenesis or
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precursor cell fate in the cerebral cortex. This conclusion was based on the observation
that in PACAP-treated animals, subsequent administration of BrdU resulted in the
appearance of cortical plate cells in which BrdU immunoreactivity colocalized with
neuronal markers, but not with glial markers. However, this observation appears to be
consistent with an effect of PACAP on neural precursors that would differentiate into
astrocytes. Indeed, if PACAP inhibits proliferation by preventing entry into S-phase
(Suh et al., 2001) and induces astrocyte differentiation in vivo, one would expect to find
that GFAP-positive cells are not immunopositive for BrdU.
Studies in which neuronal differentiation of cortical precursors was observed to
be enhanced by PACAP were performed using cells derived from E13-E14.5 embryos
(Carey et al., 2002; Lu and DiCicco-Bloom, 1997; Suh et al., 2001), a time when
neurogenesis is actively taking place. In the present study, cells were taken from older
(E17) embryos, at a time close to the onset of gliogenesis. Thus, it is possible that
PACAP could have effects on neuronal as well as glial lineages, depending on the
different cell populations affected or on the relative developmental stage of target cells.
It is known that cortical precursors from different stages of development react
differently to CNTF and BMP signaling, which act as inducers of astroglial
differentiation during late gestation. In relatively early stage cortical precursors, CNTF
does not induce astrocyte differentiation (Molné et al., 2000), and BMPs can cause
either apoptosis (Mabie et al., 1999), neuronal differentiation (Li et al., 1998) or
proliferation, depending on the type of receptor isoform expressed by target cells
(Pachinsion et al., 2001). Interestingly, it has been shown that one reason why only
older cortical precursor cells can respond to CNTF or BMP stimulation by
differentiating into astrocytes is that these cells express low levels of neurogenin.
Younger cortical precursors express higher levels of neurogenin, and this inhibits
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astrocyte differentiation by interfering with CNTF/STAT- and BMP/Smad-dependent
signaling (Sun et al., 2001). Thus, neurogenin expression at different times of
development affects cell-fate specification in response to similar extracellular signals.
Whether a similar type of mechanism applies in the case of PACAP-dependent
signaling remains to be investigated.
The type of receptor isoform on target cells can also determine the specific
biological actions of PACAP. Different PACAP receptor isoforms generated by
alternative splicing have been described. Some splice variants generate changes in the
N-terminal extracellular domain of the protein, thus influencing the selectivity of the
receptor for the ligands PACAP-27 and PACAP-38 (Pantaloni et al., 1996). Another
splice variant, named PACAPR (PAC1) TM4 (Chatterjee et al., 1996; Harmar et al.,
1998), differs by the presence of small changes in the amino acid sequence of the fourth
transmembrane-spanning domain. This receptor isoform does not work by stimulating
adenylate cyclase or phospholipase C, but by  stimulating calcium entry through an L-
type calcium channel (Chatterjee et al., 1996). In the present study, we focussed our
attention on splice variants generated by changes in the third intracellular loop, as they
affect directly the coupling of the receptor to cAMP-dependent signaling mechanisms.
Expression of PACAP receptor isoforms has been detected in the developing
central nervous system, including the rat cerebral cortex (D'Agata et al., 1996; Jaworski
and Proctor, 2000; Matsuo et al., 1994; Sheward et al., 1998; Suh et al., 2001; Waschek
et al., 1998; Zhou et al., 1999). PAC1Hop isoforms are associated with cellular
proliferation, whereas activation of the short isoform of the PAC1 receptor lacking the
Hip and Hop cassettes is associated to an antiproliferative effect (Lu et al., 1998; Nicot
and DiCicco-Bloom, 2001). In this context, the observed disappearance of the Hip/Hop
isoforms and relative enhancement of the short PAC1 receptor isoform may represent a
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functional switch to more efficiently coupling PACAP signaling to cAMP production
during the differentiation process.
Acting as a second messenger within the cell, cAMP can activate at least three
different signal transduction pathways. One of them, triggers the activation of PKA,
which phosphorylates different types of substrates including transcription factors such
as CREB. Another pathway acts through the PKA-independent activation of the
GTPase Rap-1, triggered by the direct stimulation by cAMP of a guanine nucleotide
exchange protein called cAMP-GEF or Epac (De Rooij et al., 1998; Kawasaki et al.,
1998). Finally, a third pathway has been described whose effector is another guanine
nucleotide exchange protein called CNrasGEF, which activates Ras directly (Pham et
al., 2000). To what extent PACAP stimulates any one of these pathways remains to be
determined. It has been suggested that generation of different responses following
specific stimuli acting via cAMP production may be due to intracellular
compartmentalization  allowing the coexistence of distinct cAMP signals, possibly
generated by differential activation of these pathways (Mei et al., 2002; Rich et al.,
2001). Thus, it is possible that these differences account for the lack of astrocyte
differentiation found after treatment with monoamines, despite the observation of
CREB phosphorylation in these cells. In any case, it seems that CREB phosphorylation
per se is not sufficient to trigger the astrocyte differentiation response. Indeed, we have
observed CREB phosphorylation in cortical precursor cells treated with agents such as
glutamate that do not induce differentiation (not shown).
We observed that a brief exposure to PACAP induces differentiation of cortical
precursors into astrocytes. Other investigators have found that a short exposure of
neural precursors to CNTF or BMP triggers astrocyte differentiation (Gross et al., 1996;
Park et al., 1999), whereas a short exposure to PDGF turns neural precursors into
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neurons (Williams et al. , 1997). These observations imply that once receptor activation
is accomplished, intracellular mechanisms leading to changes in gene expression are
activated in such a way that the differentiation response can proceed without further
agonist action. Although at least some of the cells that respond in this manner have
been shown to be bipotent at a minimum (Park et al., 1999), it has been shown that glial
fates can be regionally restricted early in development even before neurogenesis starts
(McCarthy et al., 2001). This notion would be in line with the observation that CNTF,
BMP and possibly PACAP, do not induce astrocyte differentiation from precursor cells
isolated at earlier developmental times.
In conclusion, we have demonstrated that PACAP induces cortical precursor
cell differentiation into astrocytes via the cAMP-dependent signaling pathway. Thus,
PACAP adds to the neurotrophic signals that can act during cortical development to
regulate astrocytogenesis.
EXPERIMENTAL METHODS
Materials. Radioactive compounds were obtained from Du Pont-New England Nuclear
(Boston, MA). Nucleotides were purchased from Pharmacia-LKB (Piscataway, NJ).
Tissue culture medium and reagents were obtained from Gibco-BRL (Grand Island,
NY). Basic FGF was from PeproTech Inc. (Rocky Hill, NJ). Rp-cAMPS (cAMP
monophosphopthioate, Rp-isomer) was purchased from Research Biochemicals
International (Natik, MA). PACAP38 and all other reagents were obtained from Sigma
Chemical Co. (St. Louis, MO) unless otherwise specified.
Primary cortical cell cultures. The cerebral cortex from fetal brains of E17 Sprague-
Dawley rats were dissected as described (McManus et al., 1999). Cell suspensions were
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prepared by trituration of the dissected pieces in Hank's Balanced Salt Solution. Once
dissociated, cells were pelleted and resuspended in serum-free DMEM containing N1
supplement (Sigma) and 1mM sodium pyruvate (defined medium) (Bottenstein and
Sato, 1979), to which bFGF (20 ng/ml) was added. Cells were seeded into poly-
ornithine-coated 10-cm dishes at a density of 2-4 x 104 cells/cm2, and incubated at 37°C.
Medium was replaced every two days, and cells were passaged before reaching
confluence (usually 5-6 days after plating) by treatment with 0.025% trypsin, which was
inactivated by adding DMEM/10% FBS. Cells were then washed, resuspended in
defined medium containing bFGF, and seeded either into 10-cm dishes for expansion
(1:3 ratio) or into 35 mm dishes for differentiation experiments, in which case plating
density was 3 x 104 cells/cm2. Cells were not trypsinized more than twice before an
experiment was carried out.
For differentiation experiments, cells incubated at 37°C for at least 24 hr after
plating were used. Basic FGF-containing medium was replaced with bFGF-free defined
medium, and one of the following compounds were immediately added: 8Br-cAMP (1
mM), noradrenaline (50 µM), dopamine (50 µM), serotonine (50 µM), PACAP (1-100
nM), or VIP (1-100 nM). After the addition of these compounds cells were incubated
for 2 or 5 days, at the end of which they were processed for immunocytochemistry.
Assessment of proliferation rates. Proliferation studies were carried out by assessing
BrdU  incorporation using an RPN 20 cell proliferation kit (Amersham, Arlington
Hights, IL) as described (McManus et al., 1999). Briefly, after treatment with BrdU (10
µM), cells were fixed in 90% ethanol/5% acetic acid and processed for
immunocytochemistry with a monoclonal anti-BrdU antibody. Control cells that had not
been exposed to BrdU were processed in parallel in an identical manner.
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Immunodetection was carried out with a biotinylated horse anti-mouse antiserum (Bio-
Rad, Hercules, CA) using nickel-ammonium-enhanced immunoperoxidase staining.
BrdU incorporation was quantified by determining the percentage of BrdU-labeled cells
relative to the total number of cells per field of vision as observed by phase-contrast
microscopy.
Immunocytochemistry. Immunocytochemistry was carried out with cells plated into
poly-ornithine-coated 35 mm tissue culture dishes after fixation in 4%
paraformaldehyde for 5 minutes. Cells were washed in phosphate buffered saline (PBS)
and permeabilized with methanol for 2 min at -20° C. Blocking was carried out with
normal goat serum (for polyclonal antisera) or normal horse serum (for monoclonal
antibodies) for 1 hr, and then cells were incubated overnight with the corresponding
primary antisera at 4°C. Polyclonal antisera used were: nestin (1:10,000 dilution)
(McManus et al., 1999), calbindin D-28K (1:1,000 dilution) (Moratalla et al., 1996),
NCAM (1:500 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA) and
galactocerebroside (1:1,000 dilution) (Sigma). Monoclonal antibodies used were: MAP-
2 (1:300 dilution) (clone HM-2, Sigma), S100β (1:500 dilution) (clone SH-B1, Sigma)
and GFAP (1:300 dilution) (clone G-A-5, Sigma). Immunodetection was carried out
with secondary biotinylated goat anti-rabbit or horse anti-mouse antisera (Bio-Rad
Laboratories, Hercules, CA) using immunoperoxidase staining with a Vectastain ABC
kit (Vector Laboratories, Burlingame, CA).
Western immunoblots. Cells were lysed in buffer containing 125 mM Tris-HCl (pH
6.8), 4% SDS, 15% glycerol, 10% β-mercaptoethanol, and 10 mM dithiothreitol.
Proteins were resolved by SDS-PAGE and blotted onto a nitrocellulose membrane.
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GFAP immunoreactivity was detected with a monoclonal antibody (clone G-A-5;
Sigma) used at a 1:10,000 dilution, followed by incubation with a horse anti-mouse
peroxidase-conjugated secondary antibody (1:5,000 dilution) (BioRad, Hercules, CA).
Phosphorylated CREB was detected with an anti-phospho-CREB monoclonal antibody
(1:2000 dilution) (New England Biolabs, Beverly, MA). CREB immunoreactivity was
detected with a rabbit polyclonal antiserum (1:500 dilution) (Santa Cruz Biotechnology,
Santa Cruz, CA), followed by incubation with a goat anti-rabbit peroxidase-conjugated
secondary antibody (1:10,000 dilution) (BioRad, Hercules, CA). Immunoreactive bands
were visualized using an enhanced chemiluminescence detection system (ECL,
Amersham, Buckinghamshire, England).
RT-PCR/Southern blot hybridization. Total RNA (10 µg) was purified from primary
cortical cells prepared from rat embryos using Triazol (Gibco), and then it was primed
with poly-(dT)15 and incubated with avian myeloblastosis virus reverse transcriptase
(Boehringer Mannheim Biochemicals, Indianapolis, IN) to synthesize cDNA. Three
different aliquots of this cDNA were used as templates to detect the expression of the
PACAP or VIP receptors PAC1, VPAC1 and VPAC2 by PCR. Specific pairs of primers
used to amplify cDNAs coding for each receptor were identical to those described
earlier to detect their expression in the rat retina (D'Agata and Cavallaro, 1998). These
were as follows: PAC1 receptor forward primer, 5’-CATCCTTGTACAGAAGCTGC-
3’; PAC1 receptor reverse primer, 5’-GGTGCTTGAAGTCCATAGTG-3’; VPAC1
receptor forward primer, 5’-CACGAGTGTGAGTACCGTCA-3’; VPAC1 receptor
reverse primer, 5’-CGGTCTTCACGGTATTGTAG-3’; VPAC2 receptor forward
primer, 5’-TCTTCAGGAAGCTGCACTGC-3’; and VPAC2 receptor reverse primer,
5’-CAAACACCATGTAGTGGACG-3’.
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PCR conditions for amplifications were 95 ºC for 5 minutes, followed by 27
cycles of 94 ºC for 30 seconds, 60 ºC for 30 seconds, and 72 ºC for 30 seconds, after
which a 5 minute incubation at 72 ºC followed. The expected sizes of the different PCR
products are as follows: 303 bp for the unspliced form of PAC1; 387 bp for PAC1
isoforms containing either the Hip or the Hop cassettes; 471 bp for the PAC1 isoform
containing both Hip and Hop cassettes; 333 bp for the VCAP1 receptor; and 583 bp for
the VPAC2 receptor. After PCR, aliquots of each reaction were resolved in 1% agarose
gels. Identical aliquots were distributed in three different segments of the gel, which
were then blotted onto three separate nylon membranes. Each membrane was probed
with a different 32P-labeled oligonucleotide specific for each type of receptor, designed
to hybridize within the amplified segment. The sequences of these oligonucleotides are
as follows: PAC1 receptor probe, 5’-ATGGAGGAGCTGGAAGGTGAAC-3’,
corresponding to nucleotides 1660-1681 of the PAC1 receptor cDNA (Hashimoto et al.,
1993); VPAC1 receptor probe, 5’-AGCTGCACTGAAGAGGGCTGGT-3’,
corresponding to nucleotides 368-389 of the VPAC1 receptor cDNA (Ishihara et al.,
1992); and VPAC2 receptor probe, 5’-TGTTTCCTGGCCTACCTTCTTA-3’,
corresponding to nucleotides 783-804 of the VPAC2 receptor cDNA (Lutz et al., 1993).
Membranes were subsequently washed and autoradiographed at -70°C.
To determine which one of the different splice variants of the PAC1 receptor are
expressed in primary cortical cells from rat embryos, PCR reactions were carried out as
described above. After PCR, aliquots of the reactions were resolved in 1% agarose gels,
blotted onto nylon membranes, and probed with 32P-labeled oligonucleotides that
hybridize specifically to either the Hip cassette (5’-
AGACTGAGAGTCCCCAAGAAAAC-3’) or to the Hop cassette (5’-
CAAGATGTCAGAACTATCCACCA-3’) (Spengler  et al., 1993). The PAC1 receptor
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probe described in the previous paragraph is common for both spliced and unspliced
isoforms of the PAC1 receptor (see Fig. 6A).
Determination of intracellular levels of cAMP. Cells were treated with either VIP or
PACAP in the presence of 2 mM isobutylmethylxantine (IBMX, Sigma). Control cells
were treated with IBMX only. Fifteen minutes after the onset of treatment, the medium
was aspirated and cAMP was extracted by adding 50 mM HCl. The concentration of
cAMP was then determined by radioimmunoassay as described (Schipani et al., 1993).
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FIGURE LEGENDS
Figure 1. A. Lack of astrocyte differentiation in response to exposure of cortical
precursor cells to monoamines. Cortical cells from E17 rat brains were cultured in
serum-free defined medium containing 20 ng/ml bFGF. After withdrawal of bFGF, cells
were left untreated (-) or were treated for 2 days with 8Br-cAMP (1 mM), noradrenaline
(NA, 50 µM), dopamine (DA, 50 µM), or serotonine (5-HT, 50 µM). Cells were then
fixed and processed for immunocytochemistry with a monoclonal anti-GFAP antibody.
The percentage of GFAP-positive cells relative to the total number of cells per field of
vision (fov) is depicted. Values represent mean + s.e.m. of data gathered from three
experiments carried out in duplicate. At least 10-12 non-overlapping fov per dish were
examined. B, Phosphorylation of CREB in response to treatment of primary cortical
precursor cells with monoamines or 8Br-cAMP at concentrations indicated above. Cells
were lysed 10 minutes after the onset of treatment and processed for western
immunoblot with an anti-phospho-CREB antiserum (top panel) or with an antiserum
that does not discriminate between CREB and phospho-CREB (bottom panel).
Figure 2. A, Generation of GFAP-expressing cells from primary cortical precursor cells
induced by PACAP, but not by VIP. Cortical cells from E17 rat brains were cultured in
serum-free defined medium containing 20 ng/ml bFGF. After withdrawal of bFGF, cells
were left untreated (-) or were treated for 2 days with PACAP or VIP at the indicated
concentrations. Cells were then fixed and processed for immunocytochemistry with a
monoclonal anti-GFAP antibody. The percentage of GFAP-positive cells relative to the
total number of cells per field of vision (fov) is depicted. Values represent mean +
s.e.m. of data gathered from three experiments carried out in duplicate. At least 10-12
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non-overlapping fov per dish were examined. B, Western immunoblot showing the
increase in GFAP induced by PACAP. After withdrawal of bFGF, cells were left
untreated (-) or were treated with 100 nM PACAP for 2 days. CREB immunoreactivity
was used as a control to monitor equal protein loading into each lane.
Figure 3. Astroglial differentiation of primary cortical precursor cells induced by
PACAP. Cells were cultured in defined medium in the presence of bFGF (20 ng/ml),
and processed for immunostaining of GFAP (left panel) or nestin (right panel). After
withdrawal of bFGF, cells were treated with PACAP (100 nM) for either 2 days or 5
days, after which they were fixed and processed for immunocytochemistry for GFAP
(left panels) or nestin (right panels). Note that cells with more elaborate morphology
exhibit less intense nestin immunostaining (bottom right panel).
Figure 4. Transient exposure of cortical precursor cells to PACAP results in astrocyte
differentiation. Cortical cells from E17 rat brains were cultured in serum-free defined
medium containing 20 ng/ml bFGF. After withdrawal of bFGF, cells were left untreated
(-) or were treated for the indicated periods of time with PACAP (100 nM). After
PACAP treatment, defined medium without bFGF was replaced. Two days after bFGF
withdrawal, cells were fixed and processed for immunocytochemistry with a
monoclonal anti-GFAP antibody. The percentage of GFAP-positive cells relative to the
total number of cells per field of vision (fov) is depicted. Values represent mean +
s.e.m. of data gathered from three experiments carried out in duplicate. At least 10-12
non-overlapping fov per dish were examined
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Figure 5. Cortical precursor cells express predominantly the PACAP-selective PAC1
receptor. Depicted is a representative RT-PCR/Southern blot hybridization experiment.
Total RNA purified from primary cortical precursor cells cultured in serum-free defined
medium in the presence of bFGF was primed with poly-(dT)15 and incubated with avian
myeloblastosis virus reverse transcriptase to synthesize cDNA. Three independent
aliquots of this cDNA were used for PCR amplifications with primers specific for
PAC1, VPAC1, or VPAC2 receptors. After PCR, aliquots of the reactions were
resolved in 1% agarose gels. Three separate gels were used, and these were blotted onto
nylon membranes, each of which was probed with a 32P-labeled internal primer specific
for each type of receptor, designed to hybridize within the amplified fragment. Probes
used to hybridize each membrane are indicated at the bottom.
Figure 6. A, Schematic depiction of the structure of the PAC1 receptor. Alternative
splicing of exons encoding the Hip and Hop domains of the third intracellular loop can
generate four different PAC1 receptor isoforms: 1) No cassette spliced in; 2) Hip; 3)
Hop; and 4) Hip and Hop. Indicated by arrows and bars are regions of the receptor
encoded by the PCR primers and oligonucleotide probes used in RT-PCR/Southern blot
hybridization experiments carried out to determine which of these receptor isoforms are
expressed in primary cortical precursor cells. B, Splice variants of PAC1 receptor
isoforms expressed in primary cortical precursor cells. RT-PCR/Southern blot
hybridization was carried out with total RNA (10 µg) purified from primary cortical
precursor cells cultured in the presence of bFGF. PCR amplification was carried out
with forward and reverse PAC1-specific primers as indicated in A.  After PCR,  aliquots
of the reactions were resolved in 1% agarose gels, blotted onto nylon membranes, and
probed with 32P-labeled internal oligonucleotides specific for each type of receptor
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isoform. Rec denotes a receptor probe that does not discriminate among different
isoforms of the PCA1 receptor, as indicated in A. C, Cyclic AMP stimulation alters the
expression of alternatively spliced isoforms of PAC1 receptors. RT-PCR/Southern blot
hybridization carried out with total RNA (10 µg) purified from primary cortical cells
induced to differentiate into astrocytes by treatment with 8Br-cAMP (1 mM) after
withdrawal of bFGF. PCR primers and oligonucleotide probes correspond to those
indicated in A.
Figure 7. A, Production of cAMP in cortical precursor cells after treatment with
PACAP or VIP. Cells were plated on 35 mm dishes and cultured in serum-free defined
medium with 20 ng/ml bFGF. Basic FGF was withdrawn from the medium and cells
were treated with IMBX (2 mM) alone (-) or with IBMX and VIP (10 or 100 nM) or
PACAP (10 or 100 mM) for 15 minutes. The medium was aspirated and cAMP was
extracted and determined by radioimmunoassay. Values represent mean + s.e.m. of
three independent experiments carried out in duplicates. B, Inhibition of PACAP-
induced astrocyte differentiation by the cAMP antagonist Rp-cAMPS (10 µM). The
cAMP antagonist was added to cells 5 minutes before PACAP (100 nM). Cells were
fixed and processed for immunocytochemistry with a monoclonal anti-GFAP antibody 2
days after treatment. The percentage of GFAP-positive cells relative to the total number
of cells per field of vision (fov) is depicted. Values represent mean + s.e.m. of data
gathered from three experiments.












